GoodRx Holdings, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
GDRX$3.65+4.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| (in thousands, except par values) | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $235,710 | $261,820 |
| Accounts receivable, net | 232,721 | 235,746 |
| Prescription reimbursement assets | 753,530 | 98,331 |
| Prepaid expenses and other current assets | 44,507 | 47,205 |
| Total current assets | 1,266,468 | 643,102 |
| Property and equipment, net | 11,742 | 12,268 |
| Goodwill | 430,331 | 430,331 |
| Intangible assets, net | 61,167 | 64,082 |
| Capitalized software, net | 140,191 | 139,261 |
| Operating lease right-of-use assets, net | 28,748 | 28,808 |
| Deferred tax assets, net | 53,042 | 57,111 |
| Other assets | 29,562 | 29,095 |
| Total assets | $2,021,251 | $1,404,058 |
| Liabilities and stockholders' equity | ||
| Current liabilities | ||
| Accounts payable | $14,525 | $19,405 |
| Prescription reimbursement liabilities | 750,978 | 130,139 |
| Accrued expenses and other current liabilities | 83,719 | 86,705 |
| Current portion of debt | 5,000 | 5,000 |
| Operating lease liabilities, current | 4,976 | 4,753 |
| Total current liabilities | 859,198 | 246,002 |
| Debt, net | 482,422 | 483,264 |
| Operating lease liabilities, net of current portion | 48,953 | 49,789 |
| Other liabilities | 8,692 | 8,741 |
| Total liabilities | 1,399,265 | 787,796 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity | ||
| Preferred stock, $0.0001 par value; 50,000 shares authorized and nil shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 103,613 and 107,088 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively; and Class B: 1,000,000 shares authorized, 233,964 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 34 | 34 |
| Additional paid-in capital | 2,031,357 | 2,026,802 |
| Accumulated deficit | (1,409,405) | (1,410,574) |
| Total stockholders' equity | 621,986 | 616,262 |
| Total liabilities and stockholders' equity | $2,021,251 | $1,404,058 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.